ASX Life Sciences stocks: Mr. Biotech thinks that 2023 could be a very good year to buy them

Marc Kennis Marc Kennis, May 1, 2023

ASX Life Sciences stocks are back, baby!

ASX Life Science stocks have suffered heavily in 2022 due to investors shifting out of risk assets, resulting in a bear market for biotech and medical devices. However, our own Mr. Biotech, Stuart Roberts, believes that now is a good time to buy ASX Life Science stocks, as many high-quality businesses are being overlooked due to poor sentiment.

The bear market has wiped out stocks that were overvalued due to COVID-19 enthusiasm and attracted tourist investors. Stuart sees this as an opportunity to invest in undervalued companies with potential for disruption, although they are currently trading below net asset backing and below cash.

He says stocks to look at include Race Oncology (ASX: RAC), Paradigm Biopharmaceuticals (ASX: PAR), Prescient Therapeutics (ASX: PTX).

 

ASX Life Science stocks

Stuart Roberts on AusBiz talking ASX Life Sciences stocks

 

Stocks Down Under Concierge gives you timely BUY and SELL alerts on ASX-listed stocks!
With price targets, buy ranges, stop loss levels and Sell alerts too.

 

GET A 3-MONTH FREE TRIAL TO CONCIERGE TODAY

 

There’s no credit card needed – the trial expires automatically.

 

 

 

Blog Categories

Get Our Top 5 ASX Stocks for FY25

Recent Posts

Orthocell

Orthocell (ASX:OCC): All systems go for a US market roll out of its flagship Remplir nerve repair product

Orthocell (ASX:OCC) is the latest ASX biotech to obtain FDA approval. Its nerve repair product Remplir was already approved in…

how tariffs impact the stock market

Here’s how tariffs impact the stock market and its investors

Many would be wondering how tariffs impact the stock market and its investors. On ‘Liberation Day‘, the returned President Trump…

oldest companies on the ASX

What are the oldest companies on the ASX? Here are 5 of them and the secrets to their success!

In this article, we look at 5 of the oldest companies on the ASX. Now, we are not claiming these…